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Background and aims: Human hepatocellular carcinoma (HCC) is one of the most common
malignancies worldwide. Polymorphisms of the TP53 gene are known to play an important
role in HCC. It is aimed to investigate the impact of the Arg72Pro polymorphism of TP53 in
the development of HCC among chronic hepatitis C patients with different stages of liver
disease.
Subjects & methods: This study included 69 HCC patients, 101 liver cirrhosis (LC) patients and
46 healthy, unrelated, age-matched volunteers as controls, from the same locality of Egypt.
The HCC and LC patients were suffering from HCV infection. The Arg72Pro polymorphism
of codon 72 was tested by PCR, followed by restriction enzyme digestion (PCR-RFLP).
Results: The results showed that the Proline allele significantly increases the risk of HCC
development (OR 2.461, 95% CI 1.391e4.3558, P ¼ 0.002, Z* ¼ 3.094), compared with the
development of LC. The variant genotypes were also associated with the risk of HCC (Pro/
Pro: OR 3.7956, 95% CI 1.9228e7.4923, P ¼ 0.0001; Arg/Pro: OR 2.099, 95% CI 1.0911e4.0383,
P ¼ 0.0263; Arg/Arg: OR 1.9594, 95% CI 1.0023e3.8306, P ¼ 0.0492). There was a significant
decrease in the plasma TP53 level in the HCC group when compared with the LC group or
with the control group (P ¼ 0.000).
Conclusion: This caseecontrol analysis confirmed that the Pro/Pro (C/C) genotype and the
Pro (C) allele of TP53 codon 72 are associated with increased risk of HCC in HCV-infected
patients. Additionally, the data suggest that the plasma TP53 level is downregulated in
HCC.
Copyright ª 2013, Mansoura University. Production and hosting by Elsevier B.V. All rights
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Hepatocellular carcinoma (HCC) is the fifth most common
cancer worldwide and the third leading cause of cancer death,
exceeded only by cancers of the lung and stomach [1]. Because
of its high fatality rates, the prevalence and mortality rates are
approximately equal [2]; however, these values vary among
different countries. Most cases of HCC occur in Asia [3]. The
development of HCC is multifactorial, resulting from the
interaction of environmental factors (possibly hepatitis vi-
ruses) and host factors (genetic factors) [4]. Hepatitis C virus
(HCV) infection is an important global health problem, as well
as the major cause of end-stage liver disease such as liver
cirrhosis (LC) and HCC. Most HCV-infected patients become
chronic hepatitis sufferers; some of them may develop liver
cirrhosis after years of follow-up, which will be followed by
HCC [5]. Among the genetic factors, polymorphisms of theTP53
gene have been associated with HCC; however, their impacts
on the progression of liver disease remain controversial [6].
TP53 is a tumor suppressor gene (OMIM no. 191170) located
on chromosome 17p13.1, and it encodes a 53-kDa nuclear
phosphoprotein, which plays a central role in safeguarding
the integrity of the human genome [7]. In the cell, the TP53
protein binds to the DNA, stimulating the production of a
protein, p21. P21 interacts with a cell division-stimulating
protein (cdk2), which acts as a tumor suppressor protein.
P53 gene mutations and polymorphisms have been widely
associated with cancer [8]. Because the loss of TP53 function
has been suggested to be the most important step in multi-
stage hepatocarcinogenesis, TP53 is a potential candidate to
decrease the risk of HCC [9]. The codon 72 polymorphism isFig. 1 e Genotyping of codon 72 of Tp53 gene. (A) Ethidium bro
digestion with BSTUI enzyme. 1 [ Ladder, 2 [ Blank, 3 [ Undi
Arg. (B) sequencing analysis. 1 [ Arg/Pro, 2 [ Pro/Pro, 3 [ Arglocated in exon 4 of the TP53 gene, a region containing very
few mutations. The TP53 protein exhibits a common poly-
morphism at amino acid 72, resulting in the substitution of an
Arginine (Arg) residue (CGC) with Proline (Pro) residue (CCC),
designated as TP53 Arg72Pro (ace no dbSNP ID: rs1042522) [10].
The aim of this study was to investigate the association
between the TP53 Arg72Pro polymorphism and the risk of HCC
in HCV-infected patients. Additionally, we investigated the
relation between the TP53 Arg72Pro polymorphism and the
plasma TP53 levels in HCC patients.2. Subjects and methods
This is a hospital-based caseecontrol study that included 69
HCC patients, 101 LC patients and 46 healthy volunteers as
controls. The HCC and LC patients were suffering from HCV
infection. All of the patients were recruited from the Clinics of
Tropical Medicine Department, Mansoura University during
the period from January 2012 to March 2013. An informed
consent was taken from all of the participants before the
study. In addition, an approval was obtained from the ethical
and scientific committees of the local health authorities.3. Inclusion criteria
All of the 69 HCC patients were diagnosed with HCC, based on
either triphasic CT scans, positive histologic findings of focal
lesions or an elevated a-fetoprotein (AFP) level (400 ng/ml),
combined with at least one positive image on angiography,mide stain 1.5% agarose gel for different genotyping after
gested PCR product, 4,5 [ Pro/Pro, 6 [ Arg/Pro, 7,8 [ Arg/
/Arg.
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mography. Furthermore, ultrasound-guided liver biopsy was
performed, and at least two strips of liver tissue measuring
2 cm in length were obtained. Liver specimens were prepared
with the hematoxylin and eosin stains and the Mason tri-
chrome stain for histological evaluation. All of the patients
were newly diagnosed, previously untreated (neither chemo-
therapy nor radiotherapy) and free from any other cancer. The
selection criteria for the 101 LC patients with no evidence of
HCC were defined either by histology or using the combina-
tion of clinical, laboratory and endoscopic tests. The absence
of HCC was established by the absence of focal lesions on the
triphasic CT scan and by an AFP level (<400 ng/ml). The LC
patients included in the study had no previous histories of
cancer and frequency matching to the cases on sex and age.
Both theHCC and LC patientswere positive to the anti-HCVAb
(3rd generation) test. Additionally, theHCVRNAwas extracted
from their serum and amplified using molecular methods.
Furthermore, lab investigations were performed on all serum
samples, for bilirubin (Total & Direct), aspartate aminotrans-
ferase (AST/GOT), alanine aminotransferase (ALT/GPT), albu-
min (Alb), alkaline phosphatase (ALP) and a-feto protein.
The exclusion criteria included autoimmune hepatitis,
HBV, dietary aflatoxin, alcohol, fatty liver disease, obesity and
diabetes. This study was performed with the approval of the
Ethical Committee of the faculties of Science and Medicine,
Mansoura University.4. Collection of blood samples
All of the subjectswere instructed to fast for at least 12 h. A 10-
ml blood sample was drawn. Five ml of this sample was
delivered to centrifuge tubes containing k2EDTA. One ml of
this EDTA anti-coagulated blood sample was stored at 30 C
for DNA extraction, whereas the remaining 4 ml was used to
obtain plasma for measuring plasma TP53 levels. The
remaining 5 ml from the withdrawn blood sample was
allowed to clot for 15 min and centrifuged at 7000 rpm for
10 min to achieve serum separation and the subsequent
determination of: activities of liver enzymes (GPT, GOT and
alkaline phosphatase) and serum levels of total bilirubin,
direct bilirubin, albumin and a-fetoprotein.5. DNA extraction from blood samples
Genomic DNA was extracted from the peripheral whole blood
using a DNA extraction kit (AxyPrep Blood Genomic DNA Mini-
prep Kit) in accordance with the manufacturer’s protocol. The
extracted DNA was stored at 20 C until further use. The
genotypes of TP53 were determined using PCR-based restric-
tion fragment length polymorphism (RFLP) method.6. Genotyping of TP53 Arg72Pro
polymorphism
Polymerase chain reaction (PCR) was performed in a DNA
thermal cycler (TECHEN TC-312, Model FTC3102D, BarloworldScientific Ltd., Stone, Stafford Shire, st 150 SA, UK), using the
Taq-PCR reaction mix purchased from Fermentas Interna-
tional Inc., Canada. The PCR mixture was prepared for each
sample containing approximately 2 of the ready master
mix, 25 pmol of forward primer 50-TGAGGACCTGGTCCTCT
GACT-30, 25 pmol of reverse primer 50-AAGAGGAATCC
CAAAGTTCCA-30 and 100 ng of template DNA. The thermal
cycling conditions were initial denaturation at 95 C for 5 min,
followed by 35 cycles of 94 C for 30 s, 55 C for 60 s and 72 C
for 30 s, with a final extension at 72 C for 10 min. The PCR
product was subjected to electrophoresis using a 1.5%
ethidium bromide-stained agarose gel.
The PCR product was then digested overnight at 37 C with
the BstUI restriction enzyme (Fermentas, Canada). The diges-
ted products were then electrophoresed on a 2% agarose gel
and visualized in UV light after ethidium bromide staining.
Genotyping was performed using a gel documentation system
(Chemi XRS Gel Documentation System) as follows: Pro/Pro
gives a single band of 416 bp and Arg/Arg gives two bands,
161 bp and 263 bp. All of the samples were genotyped twice in
two different PCR and digestion sets. Twenty samples from
each group with different genotypes were re-genotyped using
an ABI Prism BigDye Terminator version 3.1 Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA) accord-
ing to the manufacturer’s standard protocol.7. Estimation of plasma TP53 level
The quantitative determination of TP53 levels was performed
using Human TP53 ELISA kits (Immuno-Biological labora-
tories, Inc., 8201 Central Ave NE, Suite P, Minneapolis, MN
55432). This assay employs the quantitative sandwich ELISA
technique, which measures TP53 in the plasma. It was per-
formed according to the manufacturer’s instructions. The
absorbance of each sample was read on a plate ELISA reader
(Tecan, Sunrise Absorbance reader) at 450 nm wave length.8. Statistical analysis
The statistical analysis of the data was performed using the
Excel program and the statistical package for social science
(SPSS) program version 10. The data were reported as the
mean  standard deviation (SD) for the quantitative data and
as frequency and proportion for the qualitative data. The data
were analyzed to test for statistically significant differences
between the groups. For the quantitative data, the Student
unpaired t-test was used to compare two groups. The one-way
ANOVA test was used to compare more than two groups. The
Chi-square test was used to compare qualitative data. P is
significant if <0.05 at a confidence interval of 95%.9. Results
An agarose gel image represents the PCR-RFLP analysis of the
TP53 Arg72Pro polymorphism for LC, HCC and healthy con-
trols, using restriction endonuclease enzyme BstU I (Fig. 1.A).
The Pro allele is not cleaved by BstU I at codon 72 and has a
Table 1 e HCC vs. LC in all variables.
Control (46) LC (101) HCC (69) Significance
n (%) n (%) n (%)
Sex: M 36 (78.3%) 75 (74.3%) 59 (85.5%) c2 ¼ 3.1, P ¼ 0.08
F 10 (21.7%) 26 (25.7%) 10 (14.5%)
Mean ± SD
Age 49.6  10.5 54.99  7.5 55.6  6.2 t ¼ 0.3,P ¼ 0.6
TP53 level 1066.17  399.73 525.2  174.38 249.64  93.02 P  0.001
Alb 4.4  0.5 2.6  0.6 3.1  0.6 t ¼ 6.0, *P  0.001
T. Bil. 2.0  0.8 3.5  0.3 7.8  0.5 Z* ¼ 6.7, *P  0.001
D. Bil. 0.12  0.02 1.5  0.2 3.7  0.3 Z* ¼ 6.4, *P  0.001
GPT 27.0  5.3 43.2  2.9 51.2  2.4 Z* ¼ 3.1, *P ¼ 0.002
GOT 23.9  4.3 53.9  4.0 57.6  3.6 Z* ¼ 1.5, P ¼ 0.14
ALP 8.8  3.6 8.4  2.1 13.2  6.1 Z* ¼ 6.2, *P  0.001
AFP 6.8  1.9 28.1  5.2 1121.2  180.9 Z* ¼ 10.2, *P  0.001
Alb: albumin, T. Bil: total bilirubin, D. Bil: direct bilirubin.
GPT: Glutamyl pyruvate transaminase, ALP: alkaline phosphatase.
GOT: Glutamyl oxaloacetic transaminase, AFP: a-fetoprotein.
P significance between LC and HCC groups.
Non-significant: at P > 0.05.
Significant: at *P < 0.05.
*Z: ManneWhitney test.
n: Total number of case patients or control subjects.
t: Test was used for age. All P values are two-sided.
Table 2 e Genotype distribution and allele frequency of
the TP53 Arg72Pro polymorphism.
Controls LC HCC Significance
n (%) n (%) n (%)
Wild type (GG) 23 (50.0) 52 (51.5) 15 (21.7) c2 ¼ 15.1,
P  0.001Heterozygous (GC) 18 (39.1) 26 (25.7) 28 (40.6)
Rare allele (CC) 5 (10.9) 23 (22.8) 26 (37.7)
Allele frequency c2 ¼ 16.5,
P  0.001G 64 (69.6) 130 (64.4) 58 (42.0)
C 28 (30.4) 72 (35.6) 80 (58.0)
PIC 0.33 0.31 0.37
Homozygosity 60.9% 65.7% 56.8%
PD 59% 55% 65%
HardyeWeinberg
c2 0.26 1.104 2.532
P 0.61 0.293 0.111
PIC ¼ polymorphism information content, PD ¼ power of discrim-
ination.
n ¼ Total number of case patients or control subjects.
GG: Arg/Arg GC: Arg/Pro CC: Pro/Pro.
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cleaved by BstU I and yields two small fragments (263 bp and
161 bp). Thus, the heterozygote has three bands (414 bp,
263 bp, and 161 bp). The direct sequencing data confirm the
results of the PCR-RFLP Analysis (Fig. 1.B). The TP53 gene ex-
hibits a common polymorphism at codon 72, resulting in the
substitution of an Arg residue (CGC) by Pro (CCC), due to a
common guanine (G)/cytosine (C) single nucleotide poly-
morphism (SNP) at the second position of codon 72 in exon 4
of TP53. Three genotypes occur: Arginine homozygotes (Arg/
Arg), Proline homozygotes (Pro/Pro) and heterozygotes (Pro/
Arg).
Arg72Pro polymorphism in exon 4 has been genotyped in
all of the groups. The first group included 46 normal healthy
controls (36males and 10 females). The second group included
101 LC patients (75 males and 26 females) with long term
chronic liver disease andwithout signs and symptoms of focal
lesions associated with HCC. The third group included 69 HCC
patients (59 males and 10 females). Descriptive clinical and
laboratory data are presented in Table 1. There was a signifi-
cant increase in plasma TP53 level in both the HCC and LC
groups, compared with the control group. In addition, there
were significant increases in the activity of liver enzymes,
serum total bilirubin, serum direct bilirubin and serum a-
fetoprotein levels in the HCC group, compared with the con-
trol or with LC groups.
The frequencies of Arg/Arg, Arg/Pro and Pro/Pro genotypes
in the healthy control group were 50.0%, 39.1% and 10.9%,
respectively. In the LC group, these frequencies were 51.5%,
25.7% and 22.8%, respectively, whereas, for the HCC group,
these frequencies were 21.7%, 40.6% and 37.7%, respectively.
The allelic frequencies in the HCC group (Arg, 0.42; Pro, 0.58)
were significantly different from those in the LC group (Arg,
0.64; Pro, 0.36) and those in the control group (Arg, 0.70; Pro,
0.30) (P  0.001). The Pro/Pro genotype and the Pro allele weremore frequent in the HCC group. The Arg/Arg genotype and
Arg allele frequencies were higher in the healthy group, as
shown in Table 2.
The association between the TP53 codon 72 variant geno-
types and the development of HCC showed that the overall
risk associated with the Proline allele was OR ¼ 2.461, 95%
CI: 1.391e4.3558, with a relative risk of 1.5116, 95% CI:
1.156e1.9754. The risk associated with Proline allele carriage
was OR¼ 1.986, 95%CI: 1.1651e3.3857, P¼ 0.0081 and c2¼ 5.57,
with a relative risk of 1.1138, 95% CI: 1.0862e1.919, P ¼ 0.0112
and c2¼ 6.42. The variant genotypeswere also associatedwith
HCC risk (Pro/Pro: OR ¼ 3.7956, 95% CI: 1.9228e7.4923,
P ¼ 0.0001; Arg/Pro: OR ¼ 2.099, 95% CI: 1.0911e4.0383,
Table 3 e Association between TP53 codon 72 variant genotypes with HCC and LC groups.
Variant risk OR 95% CI Statistical values Fisher exact probability test
Lower High
GG (Arg/Arg) 1.9594 1.0023 3.8306 Z ¼ 1.967 0.0492
GC (Arg/Pro) 2.099 1.0911 4.0383 Z ¼ 2.221 0.0263
CC (Pro/Pro) 3.7956 1.9228 7.4923 Z ¼ 3.844 0.0001
Carriage of C allele 1.986 1.1651 3.3857 (c2) 5.57 0.0081
Overall C 2.461 1.391 4.3558 (Z*) 3.094 0.002
OR ¼ odds ratio, CI ¼ confidence interval, c2 ¼ chi-square, Z* ¼ z statistic.
e g y p t i a n j o u r n a l o f b a s i c a nd a p p l i e d s c i e n c e s 1 ( 2 0 1 4 ) 9e1 5 13P ¼ 0.0263; Arg/Arg: OR ¼ 1.9594, 95% CI: 1.0023e3.8306,
P ¼ 0.0492) (Table 3).
There were significant increases in the plasma TP53 levels
in the HCC group when compared with the healthy control
group or with the LC group. There was a significant increase in
the plasma TP53 level in the CC genotype, compared with the
GG genotype, in all the groups, as depicted in Table 4.
There were significant increases in the plasma TP53 levels
in carriers of at least one C allele (GC, CC), compared with
carriers of the G allele, in all the groups. Similarly, the plasma
TP53 levels were significantly higher in the carriers of at least
one C allele (GC, CC) and the G allele carriers in the HCC group,
compared with the healthy control group or the LC group, as
shown in Table 5.10. Discussion
Human HCC is one of the most common malignancies
worldwide. However, no therapy has been effective to date.
There is an urgent need to identify molecular markers for the
prediction of the disease course and for novel therapeutic
approaches [11]. The development of HCC depends onTable 4 e Association between plasma TP53 levels and
TP53 codon 72 genotypes in all studied groups.
Genotyping ANOVA
GG GC CC P1 value
Controls N 23 18 5 0.0003
Mean 1257.96 996.72 434.00a,b
SD 477.58 289.54 132.32
LC N 52 26 23 0.000
Mean 646.77c 471.00a,c 311.61a,b
SD 190.40 147.16 119.01
HCC N 15 28 26 0.000
Mean 435.47c 210.07a,c,d 185.04a,c,d




All results are expressed as mean  standard deviation (SD).
Non-significant: at P > 0.05. Significant: at P < 0.05.
a Significance between GG and GC or CC in all groups.
b Significance between GC and CC in all groups.
c Significance between control group and LC or HCC groups in all
genotyping subtypes.
d Significance between LC and HCC groups in all genotyping
subtypes.multiple factors: the interaction of environmental factors,
possibly, the hepatitis viruses, and host factors, including
genetic factors [12]. TP53 regulates a large number of genes
(>100 genes) that control numerous key tumor suppressing
functions, such as cell cycle arrest, DNA repair, senescence
and apoptosis [13]. While the activation of TP53 often leads to
apoptosis, TP53 inactivation facilitates tumor progression;
inactivation of TP53 mutations occurs in over 50% of cancers
[14]. In this study, Arg72Pro of exon 4, a single nucleotide
polymorphism in the TP53 gene, has been investigated for its
possible role in the development of HCC in HCV-infected
patients.
The results from this study demonstrated the association
of the Arg72Pro polymorphism of TP53 with the development
of HCC. The overall risk of the TP53-Pro72 variant compared
with LTC was OR ¼ 2.461, 95% CI: 1.391e4.3558, with a relative
risk of 1.5116, 95% CI: 1.156e1.9754. The TP53-Pro72 variant
carriage risk was OR ¼ 1.986, 95% CI: 1.1651e3.3857, P ¼ 0.0081
and c2 ¼ 5.57 with a relative risk of 1.1138, 95% CI:
1.0862e1.919, P ¼ 0.0112 and c2 ¼ 6.42. The variant genotypes
were also associated with HCC risk (Pro/Pro: OR ¼ 3.7956, 95%
CI: 1.9228e7.4923, P ¼ 0.0001; Arg/Pro: OR ¼ 2.099, 95% CI
1.0911e4.0383, P ¼ 0.0263; Arg/Arg: OR ¼ 1.9594, 95% CI:
1.0023e3.8306, P ¼ 0.0492). In the HCC patients, the fre-
quencies for the Arg/Arg, Arg/Pro and Pro/Pro genotypes wereTable 5 e Association between plasma TP53 levels and
carriages of at least one C allele in all studied groups.
Genotyping P1 value
GG GC þ CC
Controls N 23 23 0.001
Mean 1257.96 874.39
SD 477.58 210.5
LC N 52 49 0.000
Mean 646.77a 396.18a
SD 190.40 155.66
HCC N 15 54 0.000
Mean 435.47a 198.02a,b
SD 132.6 75.67
P2 value 0.000 0.000
All results are expressed as mean  standard deviation (SD).
Non-significant: at P > 0.05.
Significant: at P < 0.05.
P1 ¼ significance between GG and GC þ CC in all groups.
P2 ¼ significance between control, LC and HCC groups.
a Significance between control group and LC or HCC groups.
b Significance between LC and HCC groups.
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tients, these frequencies were 51.5%, 25.7% and 22.8%,
respectively (c2¼ 15.1, P 0.001). The allelic frequencies in the
HCC patients (TP53-Arg72 variant, 0.42; TP53-Pro72 variant,
0.58) were significantly different from those in the LC control
patients (TP53-Arg72 variant, 0.64; TP53-Pro72 variant, 0.36)
(c2 ¼ 16.5, P  0.001). These results support previous data
[15e18] that reported an association between the TP53
Arg72Pro polymorphism and an increased risk for HCC.
TP53 is critical in cell-cycle arrest and apoptosis after DNA
damage; alterations in its function may accelerate the pro-
gression from chronic liver disease to HCC [19]. TP53 has been
shown to localize to both the outer membrane and inner
membrane of mitochondria [20]. The TP53-Arg72 variant is
more effective in inducing apoptosis and protecting cells from
cancer development than the TP53-Pro72 variant. This might
be due to the ability of the TP53-Arg72 variant that were
localized at the mitochondrial membrane to regulate the
release of cytochrome C into the cytosol. The released cyto-
chrome C would play a pivotal role in activation of caspase-3
and apoptosis induction. This suggests that the TP53-Pro72
variant might be a weaker tumor suppressor than its TP53-
Arg72 counterpart. Thus, the TP53-Pro72 variant may be
partly associated with the apoptosis suppression of cells,
which is an accepted mechanism of tumorigenesis. Although
TP53-Pro72 binds more weakly than TP53-Arg72 to the posi-
tive regulatory protein, PIN1, a prolyl isomerase, it interacts
more readily with the inhibitory protein iASPP (inhibitor of
ASPP) [21]. These attributes also predict that TP53-Pro72 has a
weaker apoptotic potential than TP53-Arg72. This difference
could explain why the TP53-Pro variant may increase sus-
ceptibility to HCC. Moreover, the TP53-Arg72 variant was
found to suppress the transformation of primary cells to a
higher degree, comparedwith the TP53-Pro72 variant [22]. The
results of our study were consistent with these experimental
findings. Therefore, it is likely that the different functions of
TP53-Arg72 variant and TP53-Pro72 variant affect cell cycle
regulation, DNA repair capacity, apoptosis, tumor develop-
ment, tumor progression and consequently influence sus-
ceptibility to HCC.
The summary OR from meta-analyses revealed that
Caucasian individuals with the Pro/Pro had an increased risk
of HCC [23]. However, no significant association was found in
Asian individuals. This discrepancy may due to ethnic het-
erogeneity and difference in environmental factors. Moreover,
the OR value of the Caucasian group is much higher than the
Asian group, leading to a skewed overall OR [24]. In contrast
[25e27], have reported opposite findings. However, this
contrast should be considered with cautions. In addition to
the susceptible SNPs, interactions between genes and be-
tween genetic and environmental factors may influence can-
cer predisposition. Confirmation of these findings would
require further studies using larger sample sizes, focusing on
TP53 Arg72Pro transmission pattern in pedigrees.
In this study, the plasma TP53 level was significantly lower
in the HCC patients when compared with the LC group or with
the healthy controls, suggesting that the plasma TP53 level
was down regulated in HCC. Additionally, the Pro allele of the
TP53 Arg72Pro polymorphism had an increased risk of HCC
development in HCV-infected patients. This result isconsistent with previous results reported for breast cancer, by
Hewala [28], and for colon, lung, breast, ovarian and prostate
cancer, by Essmann [29,30], confirming the down-regulation
of TP53 in HCV patients compared with healthy controls.
Inactivation of TP53 gene mostly results frommutations of
this gene. To enable a TP53 gene response in cells containing
mutant TP53 and restore TP53 functions in cancer cells [28],
suggested two approaches. These strategies include either the
ectopic expression of functional TP53 or the reactivation of
mutant TP53 in tumor cells. In contrast [31e33], found an
over-expression of TP53 in HCC. These contradictory results
may be because TP53 is involved in multiple steps during the
development of HCC. Our results indicated that TP53 is
expressed in multiple stages. In the early stage of HCC, TP53
may be over expressed, resulting in higher plasma TP53 levels
when compared with healthy tissues. In contrast, in the late
stage of HCC, TP53 is down regulated, compared with healthy
tissues. To resolve this ambiguity, it is necessary to expand
the sample size for the study and identify the stage of HCC for
each patient, based on histopathological, radiological and
clinical examinations.
In conclusion, this caseecontrol analysis suggested that
Pro/Pro (C/C) genotype and Pro (C) allele of the TP53 codon 72
are associated with an increased risk of HCC in HCV-infected
patients and that the downregulation of plasma TP53 is a
feasible indicator to predict HCC.Conflict of interests
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